Skip to content

Veradermics MANE EPS (Diluted)

EPS (Diluted) at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$2.14-52.9%
Hims & Hers Health logo
Hims & Hers HealthHIMS
-$0.40-300%
Organon logo
OrganonOGN
$0.55+66.7%
PVL
Palvella TherapeuticsPVLA
-$1.20-62.2%
TTR
Turn Therapeutics Inc.TTRX
-$0.03-200%
PTH
Pelthos Therapeutics Inc.PTHS
-$3.09+3.7%

Other financials

Income statement

See full
Operating income-$29.9M-131%
Net income-$27.2M-120%

Balance sheet

See full
Cash & equivalents$168.4M+419%
Total debt$4.0K
Total equity$390.6M+744%
Total assets$397.4M

Cash flow

See full
Operating cash flow-$21.2M-59.0%
CapEx--100%
Free cash flow-$21.2M-58.7%

Valuation

See full
Market cap$5.22B+315%

Returns & leverage

See full
Return on equity-28.7%
Current ratio59.1×

Where this comes from

Reported directly by Veradermics in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: Veradermics ’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veradermics 's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Veradermics 's EPS (diluted)?
Veradermics (MANE) reported EPS (diluted) of -$1.32 in Q1 2026.
How has Veradermics 's EPS (diluted) changed year-over-year?
Veradermics 's EPS (diluted) increased by 93.3% year-over-year, from -$19.79 to -$1.32.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.